Rishaad Currimjee’s Post

How can we accelerate the delivery of innovative #health techniques and products to patients who need it? By working together to make cell, gene and tissue related therapies available to all European citizens! 💡 That’s why eight European organisations - including flanders.bio - joined forces in the European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB). By building a European interconnected value chain, the #EHAB will identify regional strengths, weaknesses, gaps and needs. 🇪🇺 Stay updated on our progress in strengthening the European landscape in Advanced Therapies and Biomaterials (AT&B) by following the EHAB page! ☝🏼 🫱🏽🫲🏾 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 BOM (Brabantse Ontwikkelings Maatschappij) (🇳🇱) - Brightlands Maastricht Health Campus (🇳🇱) - BioRegio STERN Management GmbH (🇩🇪) - A4TEC Association (🇵🇹) - Biocat, BioRegion of Catalonia (🇪🇸) - RISE Research Institutes of Sweden (🇸🇪) - MedSilesia Cluster - Silesian Medical Devices Network (🇵🇱) - flanders.bio (🇧🇪) 🙌🏽 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝗿𝘀 Provincie Noord-Brabant - Provincie Limburg - RegMed XB - Departement Economie, Wetenschap en Innovatie (EWI) - Vanguard Initiative - Generalitat de Catalunya - Leitat Technological Center - AseBio - Asociación Española de Bioempresas - Vall d'Hebron Institute of Oncology (VHIO) - Fraunhofer IPA. Funded by the European Union.

𝗧𝗵𝗲 #𝗖𝗮𝗻𝗰𝗲𝗿𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗺𝗼𝗿𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗮𝗻𝗱 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘀𝗲𝗱.  Ghazaleh Madani and her company CanChip are developing #microfluidicchips on which tumour cells and their micro environment can thrive. The innovative technology makes it possible to test combinations of active ingredients and offer cancer patients individualised and more tolerable treatment.    In this interview, Ghazaleh Madani talks about the technology behind the microfluidic chips, the establishment of her start-up at the research and innovation site in Potsdam-Golm and her grand vision of revolutionising #cancer medicine through technical innovation.    Ghazaleh Madani studied biochemistry and molecular biology at the University of Potsdam (Universität Potsdam) and decided in favour of the Potsdam Science Park out of conviction. In the interview, she says: »I never thought for a second about founding our company anywhere else in Germany. The Potsdam Science Park supported us right from the start, as did the investment bank Investitionsbank des Landes Brandenburg (ILB) and the economic development agency Wirtschaftsförderung Land Brandenburg GmbH (WFBB).’   The #tumouronachip systems that CanChip is developing in Potsdam-Golm have another important advantage: they can drastically reduce animal testing in drug development and speed up clinical trials.   📖 »𝘍𝘰𝘳 𝘢 𝘳𝘢𝘱𝘪𝘥 𝘤𝘩𝘢𝘯𝘨𝘦 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘻𝘦𝘥 𝘤𝘢𝘯𝘤𝘦𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦, 𝘸𝘦 𝘯𝘦𝘦𝘥 𝘢 𝘱𝘶𝘴𝘩 𝘰𝘶𝘵 𝘰𝘧 𝘵𝘩𝘦 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘻𝘰𝘯𝘦 𝘯𝘰𝘸,« says Ghazaleh Madani. Read the foll interview now on the PotsdamSciencePark website: https://lnkd.in/edNcbhAe 𝗪𝗲 𝗟𝗶𝘃𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲. The projects of Standortmanagement Golm GmbH in the Potsdam Science Park are co-financed by funds from the European Union and the federal state of Brandenburg. #CanChip #cancer #cancermedicine #personalisedmedicine #labonachip #multiorganchips #medicalstartups #healthstartups #drugtesting #chemotherapy #startup #BerlinBrandenburg #PotsdamSciencePark #lifesciences #health #fightcancer ©photo: CanChip/Steven Ritzer Photography

Here is a new type of drug, devised by AI, and the biotech to turn them into the clinic Archon Biosciences, a #biotech startup, has just stepped out of stealth with $20M funding to fuel AI-powered breakthroughs in #drugdiscovery and development. Leveraging "antibody cages" – unique protein structures designed by AI – Archon aims to accelerate the creation of targeted therapies, especially for complex diseases like cancer. This technology holds promise in personalizing and improving treatment efficacy, marking a major shift in #precisionmedicine. Archon's innovative approach highlights how AI isn’t just optimizing existing drug discovery methods but paving the way for entirely new treatment paradigms. It's based on research from this years nobel prize winner David Baker. Such tech-led transformations could mean faster pathways from research to real-world impact. Stay tuned as we witness AI reshaping healthcare! 🔬💡 Kudos to nobelprize winner James Lazarovits and team. #HealthcareInnovation #DrugDiscovery #AIFuture #DigitalHealth #phrama #antibodies #genAI VIB

🚀 ICGA2024 is almost here, where top minds in #CancerResearch will explore cutting-edge insights and data-driven discoveries.🚀 #ICGA2024 #Oncogenomics #PrecisionMedicine #DataDrivenDiscovery #HealthcareInnovation

🚀 We are thrilled to announce that two innovative companies, NIUM and OrganoTherapeutics, will be showcasing their groundbreaking work at the DeepTech Ventures Demo Day! NIUM offers a cutting-edge platform that supports food, clinical nutrition, and pharma companies in developing health-positive products. Their translational approach spans in-vitro models of digestion using an innovative “Gut-on-chip” platform, data analysis, bioinformatics, and digital support for nutrition interventions. 👤 Alberto Noronha & Adam Selamnia OrganoTherapeutics specializes in personalized cell-culture 3D representations of the human midbrain derived from patient-specific stem cells. They utilize this in-vitro model to test new compounds, aiming to develop new therapeutics for Parkinson’s Disease treatment. 👤 Jens Schwamborn Don't miss the chance to witness these pioneering demonstrations and interact with industry leaders. Register now at www.deeptechventures.lu 🔗 Sponsored by LuXembourg - Let's Make It Happen, University of Luxembourg, SnT, Interdisciplinary Centre for Security, Reliability and Trust, Société Nationale de Crédit et d'Investissement, Ministère de l'Économie - Luxembourg, Luxembourg Institute of Health, Luxembourg Chamber of Commerce, Institut de la Propriété Intellectuelle Luxembourg GIE (IPIL) - Luxembourg Institute of Science and Technology (LIST). #Deeptech #GoToMarket #Entrepreneurship #Research #Summit #LabToMarket #Technology #Funding #Luxembourg #LetsMakeItHappen

🧬 The Convergence of AI and Biomanufacturing: Pioneering the Future of Regenerative Medicine    Join us for a Fireside Chat at #BioFuture2024 on Wednesday, October 30, 9:00 AM ET, where we’ll explore how #AI-driven breakthroughs in #biomanufacturing are transforming regenerative medicine. Moderator Kimberly Ha, Founder & CEO of KKH Advisors, will interview Susan Hockfield, Professor, Neuroscience & President Emerita of Massachusetts Institute of Technology, and Nabiha Saklayen, CEO & Co-Founder of Cellino. They will explore how cutting-edge technologies are enabling the creation of living medicines that can regenerate tissues and organs. These personalized therapies offer new hope, providing potential curative solutions for diseases such as Parkinson’s, macular degeneration, and other age-related conditions tied to cellular degeneration. Topics include:  🔷 The transition from traditional therapeutics to personalized cellular therapy.  🔷 How living medicines derived from a patient’s own cells can potentially cure chronic diseases.  🔷 Challenges and opportunities in scaling regenerative medicines for widespread use.  🔷 Current advancements in biomanufacturing for cell therapies. 🔗 Register for this session: https://lnkd.in/ere467Q3   🗓️ View the full event agenda: https://lnkd.in/ep-4hm79    This fireside chat is part of a series of dynamic discussions at BioFuture™ 2024, taking place October 28-30 at Cure. in #NYC. Connect and engage with global leaders, innovators, and investors as they shape the future of biotechnology and healthcare. 📢 Partnering is now open—register and schedule one-to-one meetings in advance to connect with global industry leaders.    👉 Learn more about BioFuture here: https://lnkd.in/e7Zmh-iR  #Biotech #RegenMed #AI #MachineLearning #PersonalizedMedicine #Innovation #HealthEquity #FututureofHealthcare #Therapeutics #DemyColton

🚨🧬 Mirai Bio Raises $50M to Revolutionize Genetic Medicine Development 🚀 Mirai Bio, a Cambridge-based bioplatform innovation company, has secured $50M in initial funding! 💰 The founding investment was made by Flagship Pioneering, fueling the next stage of genetic medicine advancement across a wide range of therapeutic areas. 🌍 🔬 What makes Mirai Bio unique? Led by CEO Geoffrey von Maltzahn, Mirai Bio has built a machine intelligence-driven platform that addresses the key limitations in genetic medicine—delivery, design, and manufacturing. 💡 Their open platform leverages high throughput automation and in vivo multiplexing to rapidly generate data and optimize delivery to any tissue or cell type. This allows for faster, more efficient breakthroughs in genetic therapies. 🧠💥 💡 Why it matters: Mirai Bio’s technology accelerates genetic medicine development, creating a path for the next generation of treatments across a variety of diseases and therapeutic modalities. 🔍 This investment marks a significant leap toward transforming the future of healthcare. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #GeneticMedicine #BiotechInnovation #MachineIntelligence #FundingNews #HealthcareRevolution #FutureTechly

From BioNJ's recent BioPartnering Conference to the 2024 Life Sciences Report to the New Jersey Economic Development Authority (NJEDA)'s NJ Bioscience Center Incubator IMPACT Study, New Jersey's life sciences industry is making headlines. NJBIZ's latest on our life sciences scene is a must-read for companies in the industry looking to expand and thrive! More on our life sciences ecosystem: ➡️ New Jersey boasts more than 22 million square feet of existing lab space – with millions of square feet available for lease or purchase; ongoing and planned construction of life sciences campuses and hubs will increase that figure by 27% by 2026. ➡️ The state has the second-ranked manufacturing workforce in the nation, with 307% more employees than the national average. ➡️ Some 390 medical device manufacturing sites employ nearly 11,000 people across the state – 22% more than the national average. ➡️ New Jersey leads in cell and gene therapy, with 40% of all therapies in development taking place in the region.

From BioNJ's recent BioPartnering Conference to the 2024 Life Sciences Report to the New Jersey Economic Development Authority (NJEDA)'s NJ Bioscience Center Incubator IMPACT Study, New Jersey's life sciences industry is making headlines. NJBIZ's latest on our life sciences scene is a must-read for companies in the industry looking to expand and thrive! More on our life sciences ecosystem: ➡️ New Jersey boasts more than 22 million square feet of existing lab space – with millions of square feet available for lease or purchase; ongoing and planned construction of life sciences campuses and hubs will increase that figure by 27% by 2026. ➡️ The state has the second-ranked manufacturing workforce in the nation, with 307% more employees than the national average. ➡️ Some 390 medical device manufacturing sites employ nearly 11,000 people across the state – 22% more than the national average. ➡️ New Jersey leads in cell and gene therapy, with 40% of all therapies in development taking place in the region.

All investors in the panel “Biotech Funding: Navigating Challenges, Exploring Solutions” at #KnowledgeforGrowth today agreed that the craziness on the biotech capital market might be over, but that this is actual a good thing because the focus is again on substance, on matter not on hype. Christina Takke, Katrien Swerts, Jan Van den Bossche, Richard Reschen, Servaas Michielssens, PhD, CFA were the panelists and Bram Van Parys was the moderator of this session. Companies with good data will get good funding, according to the investors. And if a company can reach milestones without spending too much money, even better. This shows that the company is well organized and can manage its projects well. In Europe companies need to work on shoestring budgets more often, compared to the US, but they are also usually better at it. This is a good thing because most investors want efficient use of cash according to the speakers. And pressure on the budget often also results in smart, creative solutions. The next big think the panelists are keeping a close eye on are the technical fields of obesity, metabolism, siRNA’s, especially in neurobiology in the field of Alzheimer’s and ALS. Further, new biomarkers allow more effective clinical testing, which already resulted for example in the recent amyloid approvals. Precision fermentation, cell free fermentation with increased carbon utilization as an advantage, and capturing CO2, and growing bacteria on CO2 only are also promising fields, as are therapies in oncology brought to other fields such as immunology, as well as AI in health tech and drug development, which is expected to increase speed, reduce costs, and result in better products.